Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor-alpha, which is effective for induction and maintenance of remission in children with inflammatory bowel disease (IBD) (1–3). This evidence concerns the gene TNF and inflammatory bowel disease.